Financial Results For The Quarter And Half Year Ended On September 30,2026.
Filed with BSE · ISIN INE365Y01019 · · 16 pages · English
Summary by 6ix AI
The report highlights significant growth, with consolidated revenue more than doubling compared to the previous year, and a notable expansion in EBITDA margin. Profit after tax also returned to positive figures, contrasting with a loss in the same quarter last year.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Script Code: 541096 SUB: OUTCOME OF THE BOARD MEETING. 1. Approved and took on record the Un-audited Standalone and Consolidated Financial Results as per Indian Accounting Standards (IND AS) along-with the Limited Review Report and Management Discussion and Analysis Report for the quarter and half year ended September 30, 2026; The meeting of Board of Directors commenced at 03:00 p.m. and conclude
Bharat Parenterals Ltd. on 6ix
In the deck
Story so far
Earlier from Bharat Parenterals
- Board Meeting Outcome for Outcome Of Board Meeting
- Announcement under Regulation 30 (LODR)-Newspaper Publication
- Announcement under Regulation 30 (LODR)-Preferential Issue
- Shareholder Meeting / Postal Ballot-Scrutinizer"s Report
- Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Later from Bharat Parenterals
- Announcement under Regulation 30 (LODR)-Investor Presentation
- Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
- Clarification On Price Movement
Follow Bharat Parenterals into a list and get an email when it puts out news.
Follow Bharat Parenterals